Candel Therapeutics, Inc. (CADL) – What Are Researchers Saying About This Stock?

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $21.43.

A number of research analysts recently issued reports on the company. Stifel Nicolaus assumed coverage on Candel Therapeutics in a research note on Monday, July 13th. They set a “buy” rating and a $22.00 price objective for the company. Bank of America upgraded shares of Candel Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $12.00 to $18.00 in a research note on Monday, September 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Candel Therapeutics in a report on Thursday, October 15th. UBS Group reissued a “buy” rating on shares of Candel Therapeutics in a research note on Monday, August 17th. Finally, Jefferies Financial Group assumed coverage on shares of Candel Therapeutics in a research report on Thursday, October 22nd. They set a “buy” rating and a $25.00 price objective on the stock.

Candel Therapeutics Stock Performance

Shares of NASDAQ CADL opened at $9.05 on Thursday. The firm’s 50-day moving average price is $10.41 and its 200-day moving average price is $8.31. The company has a quick ratio of 16.09, a current ratio of 16.09 and a debt-to-equity ratio of 0.38. The company has a market cap of $692.51 million, a PE ratio of -6.42 and a beta of -0.27. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.28). As a group, analysts anticipate that Candel Therapeutics will post -1.29 EPS for the current year.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, CTO Seshu Tyagarajan sold 7,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $12.00, for a total transaction of $84,000.00. Following the sale, the chief technology officer directly owned 76,865 shares of the company’s stock, valued at $922,380. This trade represents a 8.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 14.30% of the company’s stock.

Institutional Trading of Candel Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. AlphaCentric Advisors LLC raised its position in shares of Candel Therapeutics by 4.3% during the third quarter. AlphaCentric Advisors LLC now owns 38,259 shares of the company’s stock valued at $399,000 after buying an additional 1,576 shares during the last quarter. Alps Advisors Inc. lifted its holdings in shares of Candel Therapeutics by 36.4% in the third quarter. Alps Advisors Inc. now owns 101,401 shares of the company’s stock worth $1,059,000 after buying an additional 27,038 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Candel Therapeutics during the third quarter worth $41,000. Profund Advisors LLC boosted its position in shares of Candel Therapeutics by 16.1% during the third quarter. Profund Advisors LLC now owns 33,301 shares of the company’s stock worth $348,000 after acquiring an additional 4,624 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Candel Therapeutics by 19.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,962 shares of the company’s stock worth $152,000 after acquiring an additional 2,301 shares during the last quarter. Institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc is a clinical-stage biopharmaceutical company developing biological immunotherapies designed to stimulate the immune system to recognize and attack cancer. The company’s approach uses engineered viral therapies intended to promote immunogenic cell death and generate broader, potentially systemic antitumor immune responses.

Candel’s pipeline includes CAN-3110, an investigational oncolytic immunotherapy based on a genetically engineered herpes simplex virus type 1.